Pharmaceuticals

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

Profitable and with little debt, this holding company is leveraging a diverse portfolio as it prepares for a major stock market uplist. Here's a closer look.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

New long-term data shows duvakitug maintained remission in IBD patients for nearly a year, positioning it as a top contender in a new class of therapy.

The new patent protects a technology that stabilizes 'undruggable' proteins, paving the way for next-gen drugs and fortifying the company's market position.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

A new study uses PET-CT scans to track CIT-013, a first-in-class antibody targeting the root cause of inflammation in rheumatoid arthritis and HS.

A Swedish biotech and Belgian university secure major EU funding to advance a first-in-class drug against glioblastoma, a notoriously deadly brain tumor.

With a novel glutamate-targeting drug and a €38M cash injection, Newron aims to transform care for treatment-resistant schizophrenia.

The major CRO acquisition deepens Worldwide's oncology and FSP capabilities, signaling a strategic move in the consolidating clinical research market.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

With no approved nonsurgical options for plantar fibromatosis, Keenova's new study and late-stage trial offer a significant glimmer of hope for sufferers.